Method of diagnosing poor survival prognosis colon cancer using let-7g
AssigneesThe Ohio State University Research Foundation, The United States of America, as represented by the Secretary of the Department of Health and Human Services, National Institute of Health, Office of Technology Transfer
InventorsCarlo M. Croce, Curtis C. Harris, Aaron J. Schetter
Life of this patent
Estimating the term…
Abstract
The present invention provides novel methods and compositions for the diagnosis and treatment of colon cancers. In particular, the present invention provides diagnostics and prognostics for colon (including colon adenocarcinoma) cancer patients, wherein the methods related to measuring miR levels can predict poor survival. The invention also provides methods of identifying inhibitors of tumorigenesis.
Claims18
A method to identify a human who has poor survival prognosis colon adenocarcinoma, comprising:
- a.) obtaining a colon adenocarcinoma cell containing test sample from a human;
- b.) conducting at least one hybridization assay of the sample so as to obtain physical data regarding the expression level of let-7g gene product in the sample;
- and
- c.) identifying the human as one who has increased risk of poor prognosis colon adenocarcinoma if the physical data indicate that the expression level of let-7g gene product is higher in the test sample than the expression level of let-7g gene product of a control.
A method to identify a human who has poor survival prognosis colon adenocarcinoma, comprising:
- a.) obtaining a colon adenocarcinoma cell containing test sample from a human;
- b.) conducting at least one hybridization assay of the sample so as to obtain physical data to determine whether the expression level of let-7g gene product in the sample is higher than expression level of let-7g gene product in control sample from a healthy subject;
- c.) comparing the expression level of let-7g gene product in the sample with let-7g expression in a control sample from a healthy subject;
- and
- c.) identifying the human as one who has increased risk of poor prognosis colon adenocarcinoma if the physical data indicate that the expression level of let-7g gene product is higher in the test sample than the expression level of let-7g gene product of control.
A method of diagnosing whether a subject has poor survival prognosis colon adenocarcinoma, comprising:
- (1) reverse transcribing RNA from a test sample obtained from the subject to provide a set of target oligodeoxynucleotides wherein said subject has colon adenocarcinoma;
- (2) hybridizing the target oligodeoxynucleotides to a microarray comprising let-7g specific probe oligonucleotides to provide a hybridization profile for the test sample;
- and
- (3) comparing the test sample hybridization profile to a hybridization profile generated from a control sample,
- (4) diagnosing the subject as having poor survival prognosis colon adenocarcinoma if the hybridization profile of the test sample displays an increase in signal compared to the signal of the hybridization profile of the control sample.
Dependencies are inferred from the claim text.